A A A

Indication

Neulasta® (pegfilgrastim) is a prescription medication used to reduce the risk of infection (initially marked by fever) in patients with some tumors receiving strong chemotherapy that decreases the number of infection-fighting white blood cells.

Important Safety Information

Who should not take Neulasta®?
Do not take Neulasta® if you have had an allergic reaction to Neulasta® or to NEUPOGEN® (Filgrastim).

What should I tell my health care provider before taking Neulasta®?
If you have a sickle cell disorder, make sure your doctor knows about it before using Neulasta®.

What are possible serious side effects of Neulasta®?
  • Spleen Rupture. Your spleen may become enlarged and can rupture while taking Neulasta®. A ruptured spleen can cause death. The spleen is located in the upper left section of your stomach area. Call your doctor right away if you have pain in the left upper stomach area or left shoulder tip area. This pain could mean your spleen is enlarged or ruptured.
  • A serious lung problem called acute respiratory distress syndrome (ARDS). Call your doctor or seek emergency care right away if you have shortness of breath, trouble breathing, or a fast rate of breathing.
  • Serious Allergic Reactions. Neulasta® can cause serious allergic reactions. These reactions can cause shortness of breath, wheezing, dizziness, swelling around the mouth or eyes, fast pulse, sweating, and hives. If you start to have any of these symptoms, call your doctor or seek emergency care right away. If you have an allergic reaction during the injection of Neulasta®, stop the injection. Call your doctor right away.
  • Sickle Cell Crises. You may have a serious sickle cell crisis if you have a sickle cell disorder and take Neulasta®. Serious and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving Filgrastim, a medicine similar to Neulasta®. Call your doctor right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.

What are the most common side effects of Neulasta®?
The most common side effect you may experience is aching in the bones and muscles. If this happens, it can usually be relieved with a nonaspirin pain reliever, such as acetaminophen.

What important information do I need to know about receiving Neulasta®?
  • Occasionally pain and redness may occur at the injection site. If there is a lump, swelling, or bruising at the injection site that does not go away, talk to the doctor.
  • Neulasta® should only be injected on the day the doctor has determined and should not be injected until approximately 24 hours after receiving chemotherapy.
  • The needle cover on the single-use prefilled syringe contains dry natural rubber (latex), which should not be handled by persons sensitive to this substance.

If you have any questions about this information, be sure to discuss them with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see the Neulasta® Patient Product Information and Prescribing Information.

Neulasta® Financial Help

There are programs available to help you pay for Neulasta®.

Neulasta FIRST STEP® Program

Neulasta® FIRST STEP® Program
Limits your out-of-pocket expense to $25 based on eligibility

The Neulasta FIRST STEP Program® is a Coupon Co-Pay program that can help eligible patients meet their Neulasta® deductible Deductible—The amount you must pay each year for your medical expenses before your insurance policy starts paying. Deductibles are common in fee-for-service coverage and PPOs., co-insuranceCo-insurance—Some insurance coverage requires you to pay a percentage of the cost of covered medical services, usually 20—30 percent. Your portion of the cost is the co-insurance., and/or co-paymentCo-payment—A flat fee for specified medical services required by some insurers. For example, your insurance provider may require you to pay a $10 co-payment for a doctor visit or a $50 co-payment for a hospital stay. (out-of-pocket) requirement.

Log on to www.AmgenFIRSTSTEP.com or call 1-888-657-8371 for a complete list of eligibility requirements and program restrictions.

Amgen Assist®

Patients with commercial or government insurance (including Medicare) who need additional financial assistance can be referred to independent nonprofit co-payment foundations. Amgen makes donations to these foundations that can help qualifying insured patients with out-of-pocket costs, including co-payments and premiums, to cover the medicines they need.

Amgen Assist can help patients identify which co-pay foundations they may be qualified for, and provide referrals for these foundations. Since these co-pay foundations are independent and not affiliated with Amgen, Amgen Assist cannot guarantee that a patient will receive assistance. Each foundation has its own eligibility criteria, which include an evaluation of each individual’s financial, medical, and insurance status.

For more information about co-pay support or referral to an independent co-pay foundation, contact an Amgen Assist service specialist at 1-888-4ASSIST (1-888-427-7478).

The Neulasta® First Step Prepaid MasterCard is issued by The Bancorp Bank pursuant to license by MasterCard International and this card may not be used everywhere Debit MasterCard is accepted. No cash or ATM access. MasterCard is a registered trademark of MasterCard International Incorporated. The Bancorp Bank; Member FDIC.

FIND HELPFUL INFORMATION IF YOU ARE CARING FOR SOMEONE WITH CANCER »

Indication

Neulasta® (pegfilgrastim) is a prescription medication used to reduce the risk of infection (initially marked by fever) in patients with some tumors receiving strong chemotherapy that decreases the number of infection-fighting white blood cells.

Important Safety Information

Who should not take Neulasta® (pegfilgrastim)?
Do not take Neulasta® (pegfilgrastim) if you have had an allergic reaction to Neulasta® (pegfilgrastim) or to NEUPOGEN® (Filgrastim).

What should I tell my health care provider before taking Neulasta® (pegfilgrastim)?
If you have a sickle cell disorder, make sure your doctor knows about it before using Neulasta® (pegfilgrastim).

What are possible serious side effects of Neulasta® (pegfilgrastim)?
  • Spleen Rupture. Your spleen may become enlarged and can rupture while taking Neulasta® (pegfilgrastim). A ruptured spleen can cause death. The spleen is located in the upper left section of your stomach area. Call your doctor right away if you have pain in the left upper stomach area or left shoulder tip area. This pain could mean your spleen is enlarged or ruptured.
  • A serious lung problem called acute respiratory distress syndrome (ARDS). Call your doctor or seek emergency care right away if you have shortness of breath, trouble breathing, or a fast rate of breathing.
  • Serious Allergic Reactions. Neulasta® (pegfilgrastim) can cause serious allergic reactions. These reactions can cause shortness of breath, wheezing, dizziness, swelling around the mouth or eyes, fast pulse, sweating, and hives. If you start to have any of these symptoms, call your doctor or seek emergency care right away. If you have an allergic reaction during the injection of Neulasta® (pegfilgrastim), stop the injection. Call your doctor right away.
  • Sickle Cell Crises. You may have a serious sickle cell crisis if you have a sickle cell disorder and take Neulasta® (pegfilgrastim). Serious and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving Filgrastim, a medicine similar to Neulasta® (pegfilgrastim). Call your doctor right away if you have symptoms of sickle cell crisis such as pain or difficulty breathing.

What are the most common side effects of Neulasta® (pegfilgrastim)?
The most common side effect you may experience is aching in the bones and muscles. If this happens, it can usually be relieved with a nonaspirin pain reliever, such as acetaminophen.

What important information do I need to know about receiving Neulasta® (pegfilgrastim)?
  • Occasionally pain and redness may occur at the injection site. If there is a lump, swelling, or bruising at the injection site that does not go away, talk to the doctor.
  • Neulasta® (pegfilgrastim) should only be injected on the day the doctor has determined and should not be injected until approximately 24 hours after receiving chemotherapy.
  • The needle cover on the single-use prefilled syringe contains dry natural rubber (latex), which should not be handled by persons sensitive to this substance.

If you have any questions about this information, be sure to discuss them with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see the Neulasta® Patient Product Information and Prescribing Information.

The Neulasta® First Step Prepaid MasterCard is issued by The Bancorp Bank pursuant to license by MasterCard International
and this card may not be used everywhere Debit MasterCard is accepted. No cash or ATM access. MasterCard is a
registered trademark of MasterCard International Incorporated. The Bancorp Bank; Member FDIC.
* Individual cancer patients depicted on this website are compensated spokespeople for Amgen, Inc.